As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...

SK Life Science launched its latest DTC advertising campaign for its seizure medication. 1 Road to Reduction is an ...

With uncertainty surrounding the future of government funding, the onus is being placed on the private sector to continue ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Lilly is also developing oral therapies for its gastroenterology pipeline.

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses the company's nationwide push to reduce cardiovascular risk ...